2014
Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women
Zeitler EP, Hellkamp AS, Fonarow GC, Hammill SC, Curtis LH, Hernandez AF, Al-Khalidi HR, Curtis JP, Heidenreich PA, Anstrom KJ, Peterson ED, Mark DB, Hammill BG, Sanders GD, Al-Khatib SM. Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. JACC Heart Failure 2014, 3: 159-167. PMID: 25543969, PMCID: PMC4461749, DOI: 10.1016/j.jchf.2014.09.006.Peer-Reviewed Original ResearchConceptsPrimary prevention implantable cardioverter defibrillatorsImplantable cardioverter defibrillatorHeart failureCardioverter defibrillatorOlder womenNational Cardiovascular Data Registry ICD RegistryLeft ventricular dysfunctionSignificant survival benefitSurvival of womenYears of ageMedicare claims databaseEligible patientsCause mortalityPrimary endpointVentricular dysfunctionSurvival benefitICD RegistryClaims databaseHeart failure databaseLonger survivalClinical trialsPropensity score methodsPatientsWomenSurvivalPrevalence of Guideline-Directed Medical Therapy Among Patients Receiving Cardiac Resynchronization Therapy Defibrillator Implantation in the National Cardiovascular Data Registry During the Years 2006 to 2008
Schneider PM, Pellegrini CN, Wang Y, Fein AS, Reynolds MR, Curtis JP, Masoudi FA, Varosy PD. Prevalence of Guideline-Directed Medical Therapy Among Patients Receiving Cardiac Resynchronization Therapy Defibrillator Implantation in the National Cardiovascular Data Registry During the Years 2006 to 2008. The American Journal Of Cardiology 2014, 113: 2052-2056. PMID: 24793671, PMCID: PMC4346333, DOI: 10.1016/j.amjcard.2014.03.049.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAged, 80 and overAngiotensin-Converting Enzyme InhibitorsCardiac Resynchronization TherapyCombined Modality TherapyDeath, Sudden, CardiacDefibrillators, ImplantableFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedPractice Guidelines as TopicPrevalenceRegistriesRetrospective StudiesRisk AssessmentSurvival AnalysisTreatment OutcomeUnited StatesVentricular Dysfunction, LeftConceptsGuideline-directed medical therapyCardiac resynchronization therapyImplantable Cardioverter-Defibrillator RegistryAngiotensin II receptor inhibitorΒ-blockersMedical therapyClass IReceptor inhibitorsNational Cardiovascular Data Registry Implantable Cardioverter Defibrillator RegistryCardiac resynchronization therapy defibrillator implantationLeft ventricular systolic dysfunctionSevere heart failure symptomsAngiotensin-converting enzyme inhibitorNational Cardiovascular Data RegistryClass I indicationsCRT-D implantationHeart failure symptomsVentricular systolic dysfunctionProportion of patientsSelection of patientsReal-world patientsAngiotensin-converting enzymePrevalence of guidelinesContemporaneous guidelinesQuality improvement targets
2011
Optimal Medical Therapy Use Among Patients Receiving Implantable Cardioverter/Defibrillators: Insights From the National Cardiovascular Data Registry
Miller AL, Wang Y, Curtis J, Masoudi FA, Buxton AE, Wang TY. Optimal Medical Therapy Use Among Patients Receiving Implantable Cardioverter/Defibrillators: Insights From the National Cardiovascular Data Registry. JAMA Internal Medicine 2011, 172: 64-67. PMID: 22082711, DOI: 10.1001/archinternmed.2011.466.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsDefibrillators, ImplantableGuideline AdherenceHeart DiseasesHumansRegistries
2004
Adverse Effects of β-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials
Ko DT, Hebert PR, Coffey CS, Curtis JP, Foody JM, Sedrakyan A, Krumholz HM. Adverse Effects of β-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials. JAMA Internal Medicine 2004, 164: 1389-1394. PMID: 15249347, DOI: 10.1001/archinte.164.13.1389.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedBisoprololBradycardiaCarbazolesCarvedilolDizzinessFatigueFemaleFollow-Up StudiesHeart Conduction SystemHeart FailureHumansHypotensionMaleMetoprololMiddle AgedPropanolaminesRisk FactorsRisk Reduction BehaviorSeverity of Illness IndexStatistics as TopicTreatment FailureVentricular Dysfunction, LeftWithholding TreatmentConceptsBeta-blocker therapyHeart failureAdverse effectsLeft ventricular systolic dysfunctionBeta-blocker trialsCardiovascular adverse effectsChronic heart failureHeart Failure TrialVentricular systolic dysfunctionΒ-blocker therapyRisk of hypotensionLife-saving therapyRandom-effects modelHF hospitalizationCause mortalitySystolic dysfunctionCause withdrawalsFailure TrialRandomized trialsAbsolute riskElectronic searchPatientsMEDLINE databaseTherapyAbsolute increaseAssociation Between Functional Status and Use and Effectiveness of Beta‐Blocker Prophylaxis in Elderly Survivors of Acute Myocardial Infarction
Vitagliano G, Curtis JP, Concato J, Feinstein AR, Radford MJ, Krumholz HM. Association Between Functional Status and Use and Effectiveness of Beta‐Blocker Prophylaxis in Elderly Survivors of Acute Myocardial Infarction. Journal Of The American Geriatrics Society 2004, 52: 495-501. PMID: 15066062, DOI: 10.1111/j.1532-5415.2004.52153.x.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAcute DiseaseAdrenergic beta-AntagonistsAge FactorsAgedAged, 80 and overCross-Sectional StudiesDrug PrescriptionsDrug UtilizationFemaleGeriatric AssessmentHumansLogistic ModelsMaleMultivariate AnalysisMyocardial InfarctionPatient DischargePatient SelectionPractice Patterns, Physicians'Proportional Hazards ModelsRetrospective StudiesSurvival AnalysisTreatment OutcomeUnited StatesConceptsAcute myocardial infarctionHospital dischargeFunctional impairmentElderly patientsMyocardial infarctionAcute myocardial infarction survivorsBeta-blocker prescriptionBeta-blocker prophylaxisBeta-blocker treatmentRetrospective cohort studySimilar survival benefitMain outcome measuresMyocardial infarction survivorsAcute care hospitalsEligible patientsCohort studySurvival benefitCare hospitalFunctional statusNational cohortInfarction survivorsOutcome measuresElderly survivorsPatientsCognitive impairment
2002
β-Blocker Therapy and Symptoms of Depression, Fatigue, and Sexual Dysfunction
Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. β-Blocker Therapy and Symptoms of Depression, Fatigue, and Sexual Dysfunction. JAMA 2002, 288: 351-357. PMID: 12117400, DOI: 10.1001/jama.288.3.351.Peer-Reviewed Original ResearchConceptsBeta-blocker therapySexual dysfunctionDepressive symptomsSymptoms of depressionAdverse eventsHeart failureMyocardial infarctionSignificant annual increaseAdditional reportsLipid solubilityAdverse effectsWithdrawal of therapyΒ-blocker therapyPatient-reported symptomsNumber of patientsEnglish-language articlesInclusion of trialsPlacebo groupMortality benefitRandomized trialsStudy treatmentCardiac patientsPlacebo controlRisk of fatigueClinical trials